Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies
Allogenic hematopoietic cell transplantation (HSCT) is typically the preferred curative therapy for adult patients with acute myeloid leukemia, but its use has been reduced as a consequence of limited donor availability in the form of either matched-related donors (MRD) or matched-unrelated donors (...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2016/5726132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560123149549568 |
|---|---|
| author | William A. Fabricius Muthalagu Ramanathan |
| author_facet | William A. Fabricius Muthalagu Ramanathan |
| author_sort | William A. Fabricius |
| collection | DOAJ |
| description | Allogenic hematopoietic cell transplantation (HSCT) is typically the preferred curative therapy for adult patients with acute myeloid leukemia, but its use has been reduced as a consequence of limited donor availability in the form of either matched-related donors (MRD) or matched-unrelated donors (MUD). Alternative options such as unrelated umbilical cord blood (UCB) transplantation and haploidentical HSCT have been increasingly studied in the past few decades to overcome these obstacles. A human leukocyte antigen- (HLA-) haploidentical donor is a recipient’s relative who shares an exact haplotype with the recipient but is mismatched for HLA genes on the unshared haplotype. These dissimilarities pose several challenges to the outcomes of the patient receiving such a type of HSCT, including higher rates of bidirectional alloreactivity and graft failure. In the past 5 years, however, several nonrandomized studies have shown promising results in terms of graft success and decreased rates of alloreactivity, in part due to newer grafting techniques and graft-versus-host disease (GVHD) prophylaxis. We present here a summary and review of the latest results of these studies as well as a brief discussion on the advantages and challenges of haploidentical HSCT. |
| format | Article |
| id | doaj-art-90a17c7f09f447c1a06a1010145d1476 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-90a17c7f09f447c1a06a1010145d14762025-02-03T01:28:18ZengWileyAdvances in Hematology1687-91041687-91122016-01-01201610.1155/2016/57261325726132Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic MalignanciesWilliam A. Fabricius0Muthalagu Ramanathan1Division of Hematology-Oncology, Bone Marrow Transplant Service, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue N., Worcester, MA 01655, USADivision of Hematology-Oncology, Bone Marrow Transplant Service, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue N., Worcester, MA 01655, USAAllogenic hematopoietic cell transplantation (HSCT) is typically the preferred curative therapy for adult patients with acute myeloid leukemia, but its use has been reduced as a consequence of limited donor availability in the form of either matched-related donors (MRD) or matched-unrelated donors (MUD). Alternative options such as unrelated umbilical cord blood (UCB) transplantation and haploidentical HSCT have been increasingly studied in the past few decades to overcome these obstacles. A human leukocyte antigen- (HLA-) haploidentical donor is a recipient’s relative who shares an exact haplotype with the recipient but is mismatched for HLA genes on the unshared haplotype. These dissimilarities pose several challenges to the outcomes of the patient receiving such a type of HSCT, including higher rates of bidirectional alloreactivity and graft failure. In the past 5 years, however, several nonrandomized studies have shown promising results in terms of graft success and decreased rates of alloreactivity, in part due to newer grafting techniques and graft-versus-host disease (GVHD) prophylaxis. We present here a summary and review of the latest results of these studies as well as a brief discussion on the advantages and challenges of haploidentical HSCT.http://dx.doi.org/10.1155/2016/5726132 |
| spellingShingle | William A. Fabricius Muthalagu Ramanathan Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies Advances in Hematology |
| title | Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies |
| title_full | Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies |
| title_fullStr | Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies |
| title_full_unstemmed | Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies |
| title_short | Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies |
| title_sort | review on haploidentical hematopoietic cell transplantation in patients with hematologic malignancies |
| url | http://dx.doi.org/10.1155/2016/5726132 |
| work_keys_str_mv | AT williamafabricius reviewonhaploidenticalhematopoieticcelltransplantationinpatientswithhematologicmalignancies AT muthalaguramanathan reviewonhaploidenticalhematopoieticcelltransplantationinpatientswithhematologicmalignancies |